The Role of the Insulin-Like Growth Factor System in Pre- and Postnatal Growth, Development, and Tumorigenesis

  • Charles T. RobertsJr.
Part of the Nutrition and Health book series (NH)


  • IGF action is an important regulator of pre- and postnatal growth in both experimental animals and in humans.

  • The complexity of the IGF signaling system of ligands, receptors, and binding proteins and their developmental and tissue-specific patterns of expression affords a powerful and finely orchestrated control mechanism throughout the life of the organism.

  • As a result of its ability to control growth and cell survival, the IGF system has the ability to affect, and has been implicated in, tumorigenesis in many types of cancer.

  • The IGF system has many components and aspects that make it an attractive therapeutic target for treatment of a number of disorders, including those affecting growth, cancer, and diabetes.


Prostate Cancer Risk Hybrid Receptor Ventral Prostate Weight 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Le Roith D, Bondy C, Yakar S, Liu JL, Butler A. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53–74.Google Scholar
  2. 2.
    LeRoith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocr Rev 1995; 16: 143–163.PubMedGoogle Scholar
  3. 3.
    Louvi A, Accili D, Efstratiadis A. Growth-promoting interaction of IGF-II with the insulin receptor during mouse embryonic development. Dev Biol 1997; 189: 33–48.PubMedCrossRefGoogle Scholar
  4. 4.
    Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19: 3278–3288.PubMedGoogle Scholar
  5. 5.
    Pandini G, Frasca F, Mineo R, Sciacca L, Vigneri R, Belfiore A. Insulin/insulin-like growth factor I hybrid receptors have different biological characteristics depending on the insulin receptor isoform involved. J Biol Chem 2002; 277: 39684–39695.PubMedCrossRefGoogle Scholar
  6. 6.
    Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3–34.PubMedGoogle Scholar
  7. 7.
    DeChiara TM, Robertson EJ, Efstratiadis A. Parental imprinting of the mouse insulin-like growth factor II gene. Cell 1991; 64: 849–859.PubMedCrossRefGoogle Scholar
  8. 8.
    Liu J, Baker J, Perkins AS, Robertson EJ, Efstratiadis A. Mice carrying null mutations of the genes encoding insulin-like growth factor I (Igf-1) and type 1 IGF receptor (Igflr). Cell 1993; 75: 59–72.PubMedGoogle Scholar
  9. 9.
    Baker J, Liu JP, Robertson EJ, Efstratiadis A. Role of insulin-like growth factors in embryonic and postnatal growth. Cell 1993; 75: 73–82.PubMedGoogle Scholar
  10. 10.
    Powell-Braxton L, Hollingshead P, Warburtin C, et al. IGF-I is required for normal embryonic growth in mice. Genes Dev 1993; 7: 2609–2617.PubMedCrossRefGoogle Scholar
  11. 11.
    Lau MMH, Stewart CEH, Liu Z, Bhatt H, Rotwein P, Stewart CL. Loss of the imprinted IGF2 cation-independent mannnose 6-phosphate receptor results in fetal overgrowth and perinatal lethality. Genes Dev 1994; 8: 2953–2963.PubMedCrossRefGoogle Scholar
  12. 12.
    Wang Z-Q, Fung MR, Barlow DP, Wagner EF. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/Mpr gene. Nature 1994; 372: 464–467.Google Scholar
  13. 13.
    Ludwig T, Eggenschwiler J, Fisher P, D’Ercole Ai, Davenport ML, Efstratiadis A. Mouse mutant embryos overexpressing IGF-II exhibit phenotypic features of the Beckwith-Wiedemann and Simpson-Gloabi-Behmel syndromes. Genes Dev 1997; 11: 3128–3142.PubMedCrossRefGoogle Scholar
  14. 14.
    Mathews LS, Hammer RE, Behringer RR, D’Ercole AJ, Bell GI, Brinster RL. Growth enhancement of transgenic mice expressing human insulin-like growth factor I. Endocrinology 1988; 123: 2827–2833.PubMedCrossRefGoogle Scholar
  15. 15.
    Rogler CE, Yang D, Rosetti L, et al. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor transgenic mice. J Biol Chem 1994; 269: 13779–13784.PubMedGoogle Scholar
  16. 16.
    Wolf E, Rapp K, Blum WF, Kolb H, Brem G. Skeletal growth of transgenic mice with elevated levels of circulating insulin-like growth factor-II. Growth Regul 1995; 5: 177–183.PubMedGoogle Scholar
  17. 17.
    Mann GV. The riddle of Pygmy stature. N Engl J Med 1987; 317: 709–710.CrossRefGoogle Scholar
  18. 18.
    Bailey RC. The comparative growth of Efe Pygmies and African farmers from birth to age 5 years. Ann Hum Biol 1991; 18: 113–120.PubMedCrossRefGoogle Scholar
  19. 19.
    Bailey RC. Growth of African Pygmies in early childhood. N Engl J Med 1990; 323: 1146.PubMedGoogle Scholar
  20. 20.
    Geffner ME, Bailey RC, Bersch N, Vera J, Golde DW. Insulin-like growth factor-I unresponsiveness in an Efe Pygmy. Biochem Biophys Res Commun 1993; 193: 1216–1223.PubMedCrossRefGoogle Scholar
  21. 21.
    Geffner ME, Bersch N, Bailey RC, Golde DW. Insulin-like growth factor-I resistance in immortalized T-cell lines from African Efe Pygmies. J Clin Endocrinol Metab 1995; 80: 3732–3738.PubMedCrossRefGoogle Scholar
  22. 22.
    Cortez AB, Van Dop C, Bailey RC, et al. IGF-I resistance in virus-transformed B-lymphocytes from African Efe Pygmies. Biochem Mol Med 1996; 58: 31–36.PubMedCrossRefGoogle Scholar
  23. 23.
    Hattori Y, Vera JC, Rivas CI, et al. Decreased insulin-like growth factor-I (IGF-I) receptor expression and function in immortalized African pygmy T-cells. J Clin Endocrinol Metab 1996; 81: 2257–2263.Google Scholar
  24. 24.
    Woods KA, Camacho-Huebner C, Savage MO, Clark AJ. Intrauterine growth retardation and postnatal growth failure associated with the insulin-like growth factor I gene. N Engl J Med 1996; 335: 1363–1367.PubMedCrossRefGoogle Scholar
  25. 25.
    Roback EW, Baraket Al, Dev VG, Mbikay M, Chretien M, Butler MG. An infant with deletion of the distal long arm of chromosome 15 (q26.1-gter) and loss of insulin-like growth factor I receptor gene. Am J Med Genet 1991; 38: 74–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Siebler T, Wlodzimierz L, Terry CL, et al. Insulin-like growth factor I receptor expression and function in fibroblasts from two patients with deletion of the distal long arm of chromosome 15. J Clin Endocrinol Metab 1995; 80: 3447–3457.PubMedCrossRefGoogle Scholar
  27. 27.
    Tamura T, Tohma T, Ohta T, et al. Ring chromosome 15 involving deletion of the insulin-like growth factor 1 receptor gene in a patient with features of Russell-Silver syndrome. Clin Dysmorphol 1993; 2: 106–113.PubMedCrossRefGoogle Scholar
  28. 28.
    Peoples R, Milatorich A, Francke U. Hemizygosity at the insulin-like growth factor I receptor (IGFIR) locus and growth failure in the ring chromosome 15 syndrome. Cytogenet Cell Genet 1995; 70: 228–234.PubMedCrossRefGoogle Scholar
  29. 29.
    Almeida A, Muleris M, Dutrillaux B, Malfoy B. The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chrom Cancer 1994; 11: 63–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Ogawa O, Becroft DM, Morison IM, et al. Constitutional relaxation of insulin-like growth factor II gene imprinting associated with Wilms’ tumor and gigantism. Nat Genet 1993; 5: 40812.CrossRefGoogle Scholar
  31. 31.
    Suzuki H, Veda R, Takahashi T. Altered imprinting in lung cancer. Nat Genet 1994; 6: 332–333.PubMedCrossRefGoogle Scholar
  32. 32.
    Zhan S, Shapiro DN, Helman LJ. Activation of an imprinted allele of the insulin-like growth factor II gene implicated in rhabbdomyosarcoma. J Clin Invest 1994; 94: 445–448.PubMedCrossRefGoogle Scholar
  33. 33.
    DePhino RA. The age of cancer. Nature 2000; 408: 248–254.CrossRefGoogle Scholar
  34. 34.
    Kaleko M, Rutter WJ, Miller AD. Overexpression of the human insulin-like growth factor I receptor promotes ligand-dependent neoplastic transformation. Mol Cell Biol 1990; 10: 464–473.PubMedGoogle Scholar
  35. 35.
    Turner BC, Haffty BG, Narayanan L, et al. Insulin-like growth factor-I receptor overexpression mediates cellular radioresistance and local breast cancer recurrence after lumpectomy and radiation. Cancer Res 1997; 57: 3079–3083.PubMedGoogle Scholar
  36. 36.
    Wen B, Deutsch E, Marangoni E, et al. Tyrphostin AG1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001; 85: 2017–2021.PubMedCrossRefGoogle Scholar
  37. 37.
    Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate S. Protein and mRNA for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996; 81: 3774–3782.PubMedCrossRefGoogle Scholar
  38. 38.
    Happerfield LC, Miles DW, Barnes DM, Thomsen LL, Smith P, Hhanby AM. The localization of the insulin-like growth factor receptor 1 (IGFR-1) in benign and malignant breast tissue. J Pathol 1997; 183: 412–417.PubMedCrossRefGoogle Scholar
  39. 39.
    Chott A, Sun Z, Morganstern D, et al. Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of type 1 insulin-like growth factor receptor. Am J Pathol 1999; 155: 1271–1279.PubMedCrossRefGoogle Scholar
  40. 40.
    Schnarr B, Strunnz K, Ohsam J, Benner A, Wacker J, Mayer D. Down-regulation of insulin-like growth factor-I receptor and insulin receptor substrate-1 expression in advanced human breast cancer. Int J Cancer 2000; 89: 506–513.PubMedCrossRefGoogle Scholar
  41. 41.
    Damon SE, Plymate SR, Carroll JM, et al. Transcriptional regulation of insulin-like growth factor-I receptor gene expression in prostate cancer cells. Endocrinology 2001; 142: 21–27.PubMedCrossRefGoogle Scholar
  42. 42.
    Hellawell GO, Turner GD, Davies DR, Poulsom R, Brewster SF, Macaulay VM. Expression of the type 1 insulin-like growth factor receptor is up-regulated in primary prostate cancer and commonly persists in metastatic disease. Cancer Res 2002; 62: 2942–2950.PubMedGoogle Scholar
  43. 43.
    Sperandio S, de Belle I, Bredesen DE. An alternative, nonapoptotic form of programmed cell death. Proc Natl Acad Sci USA 2000; 97: 14376–14381.Google Scholar
  44. 44.
    Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO. Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997; 76: 1115–1118.PubMedCrossRefGoogle Scholar
  45. 45.
    Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279: 563–566.PubMedCrossRefGoogle Scholar
  46. 46.
    Wolk A, Mantzoros CS, Andersson SO, et al. Insulin-like growth factor 1 and prostate cancer risk: A population-based, case-control study. J Natl Cancer Inst 1998; 90: 911–915.PubMedCrossRefGoogle Scholar
  47. 47.
    Cohen P. Serum insulin-like growth factor I levels and prostate cancer risk-interpreting the evidence. J Natl Cancer Inst 1998; 90: 876–879.PubMedCrossRefGoogle Scholar
  48. 48.
    Cohen P, Peehl DM, Lamson G, Rosenfeld RG. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab 1991; 73: 401–407.Google Scholar
  49. 49.
    Peehl DM, Cohen P, Rosenfeld RG. The insulin-like growth factor system in the prostate. World J Urol 1994; 13: 306–311.Google Scholar
  50. 50.
    Cohen P, Peehl DM, Rosenfeld RG. The IGF axis in the prostate. Horm Metab Res 1994; 26: 81–84.PubMedCrossRefGoogle Scholar
  51. 51.
    Boudon C, Rodier G, Lechevallier E, Mottet N, Barenton B, Sultan C. Secretion of insulin-like growth factors and their binding proteins by human normal and hyperplastic prostatic cells in primary culture. J Clin Endocrinol Metab 1996; 81: 612–617.PubMedCrossRefGoogle Scholar
  52. 52.
    Toning N, Vinter-Jensen L, Pederson SB, Sorensen FB, Flyvbjerg A, Nexo E. Sytemic Administration of insulin-like growth factor I (IGF-I) causes growth of the rat prostate. J Urol 1997; 158: 222–227.CrossRefGoogle Scholar
  53. 53.
    Huynh H, Seyam RM, Brock GB. Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 1998; 58: 215–218.PubMedGoogle Scholar
  54. 54.
    Ruan W, Powell-Braxton L, Kopchick JJ, Kleinberg DL. Evidence that insulin-like growth factor I and growth hormone are required for prostate gland development. Endocrinology 1999; 140: 1984–1989.PubMedCrossRefGoogle Scholar
  55. 55.
    Cutting CW, Hunt C, Nisbet JA, Bland JM, Dalgleish AG, Kirby RS. Serum insulin-like growth factor-1 is not a useful marker of prostate cancer. BJU Int 1999; 83: 996–999.PubMedCrossRefGoogle Scholar
  56. 56.
    Kurek R, Tunn UW, Eckart O, Aumuller G, Wong J, Renneberg H. The significance of serum levels of insulin-like growth factor-1 in patients with prostate cancer. BJU Int 2000; 85: 125–129.PubMedCrossRefGoogle Scholar
  57. 57.
    Djavan G, Bursa B, Seitz C, et al. Insulin-like growth factor 1 (IGF-1), IGF-1 density, and IGF-1/PSA ratio for prostate cancer detection. Urology 1999; 54: 603–606.PubMedCrossRefGoogle Scholar
  58. 58.
    Shaneyfelt T, Husein R, Bubley G, Mantzoros CS. Hormonal predictors of prostate cancer: A meta-analysis. J Clin Oncol 2000; 18: 847–853.PubMedGoogle Scholar
  59. 59.
    Finne P, Auvinen A, Koistinen H, et al. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen. J Clin Endocrinol Metab 2000; 85: 2744–2747.PubMedCrossRefGoogle Scholar
  60. 60.
    Baffa R, Reiss K, El-Gabry EA, et al. Low serum insulin-like growth factor 1 (IGF-1): A significant association with prostate cancer. Tech Urol 2000; 6: 236–239.PubMedGoogle Scholar
  61. 61.
    Harman SM, Metter EJ, Blackman MR, Landis PK, Carter HB. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictor of clinical prostate cancer. J Clin Endocrinol Metab 2000; 85: 4258–4265.PubMedCrossRefGoogle Scholar
  62. 62.
    Stattin P, Bylund A, Rinaldi S, et al. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk; a prospective study. J Natl Cancer Inst 2000; 92: 1910–1917.PubMedCrossRefGoogle Scholar
  63. 63.
    Shi R, Berkel HJ, Yu H. Insulin-like growth factor-I and prostate cancer: a meta-analysis. Br J Cancer 2001; 85: 991–996.PubMedCrossRefGoogle Scholar
  64. 64.
    Latif Z, McMillan DC, Wallace AM, et al. The relationship of circulating insulin-like growth factor 1, its binding protein-3, prostate-specific antigen and C-reactive protein with disease stage in prostate cancer. BJU Int 2002; 89: 396–399.PubMedCrossRefGoogle Scholar
  65. 65.
    Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94: 1099–1106.PubMedCrossRefGoogle Scholar
  66. 66.
    DiGiovanni J, Kiguchi K, Frijhoff A, et al. Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 2000; 97: 3455–60.PubMedCrossRefGoogle Scholar
  67. 67.
    Gnanapragasam VJ, McCahy PJ, Neal DE, Robson CN. Insulin-like growth factor II and androgen receptor expression in the prostate. BJU Int 2000; 86: 731–735.PubMedCrossRefGoogle Scholar
  68. 68.
    Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet. 1998; 351: 1393–1396.PubMedCrossRefGoogle Scholar
  69. 69.
    Bohlke K, Cramer DW, Trichopoulos D, Mantzoros, CS. Insulin-like growth factor-I in relation to premenopausal ductal carcinoma in situ of the breast. Epidemiology 1998; 9: 570–573.PubMedCrossRefGoogle Scholar
  70. 70.
    Vadgama JV, Wu Y, Datta G, Khan H, Chillar R. Plasma insulin-like growth factor-I and serum IGFbinding protein 3 can be associated with the progression of breast cancer, and predict the risk of recurrence and the probability of survival in African-American and Hispanic women. Oncology 1999; 57: 330–340.PubMedCrossRefGoogle Scholar
  71. 71.
    Byrne C, Colditz GA, Willett WC, Speizer FE, Pollak M, Hankinson SE. Plasma insulin-like growth factor (IGF) I, IGF-binding protein 3, and mammographic density. Cancer Res 2000; 60: 3744–3748.PubMedGoogle Scholar
  72. 72.
    Li BD, Khosravi MT, Berkel HJ, et al. Free insulin-like growth factor-I and breast cancer risk. Int J Cancer 2001; 91: 736–739.PubMedCrossRefGoogle Scholar
  73. 73.
    Jernstrom H, Barrett-Connor E. Obesity, weight change, fasting insulin, proinsulin, C-peptide, and insulin-like growth factor-1 levels in women with and without breast cancer: the Rancho Bernardo Study. J Womens Health Gend Based Med 1999; 8: 1265–1272.PubMedCrossRefGoogle Scholar
  74. 74.
    Agurs-Collins T, Adams-Campbell LL, Kim KS, Cullin KJ. Insulin-like growth factor-1 and breast cancer risk in postmenopausal African-American women. Cancer Detect Prey 2000; 24: 199–206.Google Scholar
  75. 75.
    Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91: 579–581.CrossRefGoogle Scholar
  76. 76.
    Manousos O, Souglakos J, Bosetti C, et al. IGF-I and IGF-II in relation to colorectal cancer. Int J Cancer 1999; 83: 15–17.PubMedCrossRefGoogle Scholar
  77. 77.
    Kaaks R, Toniolo P, Akhmedkhanov A, et al. Serum C-peptide, insulin-like growth factor (IGF)-I, IGFbinding proteins, and colorectal cancer risk in women. J Natl Cancer Inst 2000; 92: 1592–1600.Google Scholar
  78. 78.
    Palmqvist R, Hallmans G, Rinaldi S, et al. Plasma insulin-like growth factor 1, insulin-like growth factor binding protein 3, and risk of colorectal cancer: A prospective study in north Sweden. Gut 2002; 50: 642–646.PubMedCrossRefGoogle Scholar
  79. 79.
    Probst-Hensch NM, Yuan JM, Stanczyk FZ, Gao YT, Ross RK, Yu MC. IGF-1, IGF-2 and IGFBP-3 in prediagnostic serum: association with colorectal cancer in a cohort of Chinese men in Shanghai. Br J Cancer 2001; 85: 1695–1699.PubMedCrossRefGoogle Scholar
  80. 80.
    Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999; 91: 151–156.PubMedCrossRefGoogle Scholar
  81. 81.
    Lukanova A, Toniolo P, Akhmedkhanov A, et al. A prospective study of insulin-like growth factor-I, IGF-binding proteins-1, -2 and -3 and lung cancer risk in women. Int J Cancer 2001; 92: 888–892.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2004

Authors and Affiliations

  • Charles T. RobertsJr.

There are no affiliations available

Personalised recommendations